{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008934","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.211812+00:00","generated_at":"2026-06-17T22:33:25.430530+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Tenaya Therapeutics adopts amended bylaws with enhanced stockholder nomination procedures","bullets":["Enhanced disclosure requirements for stockholder director nominations and business proposals.","Updated provisions to address universal proxy rules and conform to Delaware General Corporation Law amendments.","Revised procedures for stockholder meetings, quorum, and adjourned meetings.","Clarified exclusive forum provisions and updated director, committee, and officer sections."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008934","json":"https://secwatch.observer/filing/0000950170-23-008934.json","markdown":"https://secwatch.observer/filing/0000950170-23-008934.md","text":"https://secwatch.observer/filing/0000950170-23-008934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023008934/0000950170-23-008934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023008934/tnya-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:33:25.430530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68941938aed884d5e07d21f0167c63a3685f0340","claim":"Tenaya Therapeutics, Inc.: Amended and restated bylaws to enhance procedural mechanics for stockholder nominations and other business, update DGCL provisions, and make other updates (effective 2023-03-16).","evidence_excerpt":"On March 16, 2023, the Board of Directors (the “Board”) of Tenaya Therapeutics, Inc. (“Tenaya”) approved Tenaya’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000095017023008934/0000950170-23-008934-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-16"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}